Published in:
01-07-2009 | Clinical Trial Report
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
Authors:
S. H. Waters, A. Gillibrand, H. Berry, S. Kumar, G. Velikova, D. J. Dodwell, Timothy J. Perren
Published in:
Cancer Chemotherapy and Pharmacology
|
Issue 2/2009
Login to get access
Abstract
Background
Combinations of anthracycline, taxane and fluoropyrimidine are highly active in advanced breast cancer (ABC). In a phase II study of epirubicin 50 mg/m2, docetaxel 75 mg/m2, and infusional 5-FU 200 mg/m2/day, we found dose-limiting neutropenia and frequent central venous catheter complications. An alternative approach has been tested using weekly fractionation of docetaxel, and oral capecitabine.
Methods
Initially, six women with ABC were treated with epirubicin 60 mg/m2 day 1, docetaxel 25 mg/m2 days 1,8,15, and capecitabine 1,000 mg/m2 twice daily days 1–14, every 21 days. Six further patients received the above with capecitabine escalated to 1,500 mg/m2
Results
Four DLTs occurred in six patients at the second dose level (febrile neutropenia in 2). There were frequent dose delays/reductions, and fatigue, nausea/vomiting, and diarrhoea were common. Overall, six of ten assessable patients achieved a partial response.
Conclusions
An active regimen, but significant haematological toxicity precluded dose further escalation.